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Abstract:  Infertility is defined as the failure to conceive after twelve months of unprotected intercourse.  It is a health burden with many psychological, economical, and social sequelae that can significantly decrease quality of life, and is often associated with serious medical disorders.  Male infertility of genetic origin affects as many as 1 in 40 adult men, and can therefore be considered a common disease.  Diagnosing male infertility can be a long and expensive process, involving several evaluations, tests for chemical exposures, endocrine panels, counseling, etc.  Although up to half of male infertility may be of genic etiology, genetic testing is rarely performed.  Of public health significance, Array Comparative Genomic Hybridization (aCGH) at the genomic level may be a viable tool for diagnosing male infertility of genic origin which affects up to 1 in 40 men, with clinical as well as economical utility.  However, more research needs to be done in order to realize the full potential of aCGH for diagnosing male infertility.  The Yatsenko lab of Magee-Womens Research institute and foundation is working to identify and characterize previously unknown candidate genes for male infertility and assess the usefulness of implementing aCGH as a standard of care test for diagnosing male infertility.  
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Infertility is defined as the failure to conceive after twelve months of unprotected intercourse.  It is a health burden with many psychological, economical, and social sequelae that can significantly decrease quality of life, and approximately 1-10% of cases are associated with serious medical disorders.  Infertility affects ten to fifteen percent of American couples, of which half is due to a male factor, that is, the couple’s inability to reproduce is caused by a health condition or defect in the male partner [1, 2].  Among infertile men, twenty percent have azoospermia or oligozoospermia (AZ/OZ), with nearly a third of that due to genetic defects.  Thus up to one in forty adult men may be affected by genetic infertility [3]. The cost of diagnosing and treating infertility and its complications has been estimated to exceed roughly five billion dollars per year [4, 5].  These costs are most often placed directly on patients themselves due to lack of insurance coverage of infertility diagnosis and treatment in most states [6].  One aspect of infertility that may be amenable to reductions in this cost burden to couples, as well clinics and insurance companies, is the diagnostic process.  Currently, genetic testing for infertility is very limited, and is not used as a first line diagnostic method.  In this essay, I propose that the financial burden of male infertility may be reduced through an initiative to implement array comparative genomic hybridization. This method may be cost-effective, given the high frequency of genetic causes of infertility, the utility and efficiency of this array technology, and other benefits of genetic testing for couples and their children.  
1.1	Genetics of Male infertility
Reproductive success requires thousands of necessary gene products.  The foundation of reproduction begins years before the interaction of the sperm and the oocycte, and requires careful coordination and development of multiple systems, including the germline lineage, formation of future gonads, genital tracts, etc. [].  
Up to 50% of male infertility may have a genetic etiology.  These include chromosome aneuploidies and translocations, Y-chromosome microdeletions, X-chromosome abnormalities, single gene mutations, and DNA mismatch repair and chromosomal recombination defects.  The most common chromosome aneuploidies and translocations are Klinefelter syndrome (XXY), when a male has two X and one Y-chromosome, as opposed to the normal amount of one X and one Y.  Additional chromosomal anomalies leading to male infertility include XYY syndrome, XX male syndrome, mixed gonadal dysgenesis, and Robertsonian translocations.  Known Y-chromosome microdeletions are located on the AZF region, also known as the azoospermic factor region.  Microdeletions in the AZF region account for nearly 10% of azoospermia and oligozoospermia.  The X-chromosome also contains genes important for male reproduction. Alterations such as translocations, deletions, and inversions on the X-chromosome can result in infertility and azoospermia [].  Unfortunately, knowledge of X-chromosome abnormalities causing male infertility is limited to mouse models.  However, it is postulated that similar genetic defects could cause infertility in human males.  
There are several single gene mutations known to cause male infertility.  These include, but are not limited to, Kallmann syndrome (X-linked and familial), Cystic Fibrosis and CFTR mutations, generalized Wolffian duct anomalies, persistent müllerian duct syndrome, insulin-like growth receptor mutations, androgen receptor gene mutations, Xq11-11.2, and SRY mutations.  Single gene mutations such as these typically occur in less than 1: 20,000 live deliveries.  However, mutations in the CFTR gene cause the most common autosomal recessive disease in Caucasians, cystic fibrosis, with an incidence of 1 in 2,500 live births.  CFTR mutations also account for a large portion of men with non-obstructive azoospermia, which represents about 50% of azoospermic men [] [].   
Much research is required in the area of male infertility, but developments in genomic medicine may explain a significant portion of what is now considered idiopathic male infertility.  The majority of research on the genetics of male infertility have focused on AZ/OG [].  The two types of azoospermia are obstructive, and nonobstructive.  Obstructive azoospermia is caused by a post – testicular defect that results in the failure of sperm to be transported from the testicles to the ejaculate.  This condition affects between 7 to 51 percent of men with azoospermia [], and up to 50% of men with obstructive azoospermia have Cystic Fibrosis [].  Among men with nonobstructive azoospermia, meaning no sperm is being produced by the testes, 10% have Y chromosome micro deletions in one of three regions: AZFa, AZFb, and AZFc, and about 4 % have Klinefelter syndrome (47, XXY) or other numeric chromosome abnormalities.  Overall, about 80% of men with azoospermia or oligozoospermia are considered idiopathic due to negative genetic testing.
Some work has been done to identify additional candidate genes via animal model approaches, but there have been several limitations to identify novel genes associated with male infertility.  These limitations include inappropriate controls, single gene analysis, lack of family pedigrees to corroborate significance of findings, and lack of functional studies.  1,500 genes may be involved in spermatogenesis.  Several hundred of these are expressed exclusively in male germs cells, which indicates that they could be candidates for causing isolated infertility.  However, no additional genetic causes are recognized to be important for patient care, mainly because results have not been replicated, explain small effects, or have only been observed in mouse models.  There are over 150 single gene mutations that have been found to result in male infertility in mice, most of which affect specific cell types and stages of spermatogenesis, including germ cells and Somatic cells.  These single gene defects represent vast potential for diagnosis and therapy if they are observed in men with infertility [].
1.2	Current practices In diagnosing infertility
In reproductive endocrinology, infertility, and urology clinics, identifying the etiology behind a man’s reproductive struggles is currently conducted in a systematic fashion.  The diagnostic workup rarely includes genetic testing despite increasing knowledge of genetic causes of male infertility [].  Figure 1 illustrates the current algorithm for diagnosing men with absent or low ejaculate volume, whereas figure 2 presents the algorithm in the case of a predominant semen abnormality.
For males, eliciting a cause of infertility is typically done in four parts:  history, physical examination, semen analysis, and hormone assessment.  First, several aspects of the patient’s history are considered, including attempts at paternity.  This component includes the patient’s family history; to reveal possible hereditary health problems that can be identified through relatives, such as cryptorchidism, midline defects, and hypogonadism.  The patient’s own medical history is also taken into consideration.  Important aspects of the medical history to consider are systemic illnesses such as diabetes, fevers, infections, cancer, and cystic fibrosis.  Also, prior surgeries like prostate procedures, retroperitoneal pelvic or bladder procedures, trauma, hernorraphy, and orchidopexy; all of which might impair fertility.  Important points in developmental history are prenatal diethylstilbestrol exposure, congenital anomalies, and hypospadias.  Exposures to gonadotoxins, any chemical or agent that may impair sperm production, may be revealed by taking occupational and social history.  Factors considered in an occupational history might include exposure to herbicides and heavy metals, pesticides, dyes, benzene – based solvents, chronic heat, and ionizing radiation.  For social history, alcohol, tobacco, steroid, and recreational drug use are all considered.  Lastly, history of sexual activity is taken, including use of spermicidal lubrications, and incorrect patterns of intercourse [].
The physical examination may reveal obstructive causes of infertility, or otherwise offer additional indications that warrant further evaluation.  The testes are mass irregularities, consistency, and size, measurements which may be associated with decreased sperm production.  The vas deferens must be assessed for agenesis, atresia, and injury.  Also, lipoma or varicocele may be identified upon examination the spermatic cords if asymmetry is observed.  Lastly, a rectal exam should be performed that could identify cysts, infections, or dilated seminal vesicles [].
Semen analysis does not directly diagnose infertility, but it may indicate a lowered probability of reproductive success.  Typically two semen analyses are performed following two to three days of sexual abstinence [].  Results of a normal semen analysis would include a count of at least 48 million sperm per milliliter and 63% normal morphology.  There is no set value for the percentage of sperm cells with normal morphology that is diagnostic of infertility, but it is important that this measurement is taken as it may help determine whether semen is fertile or infertile[].  If semen results are abnormal, counseling on lifestyle changes is provided to avoid gonadotropin exposure and to improve probability of fertility via coital timing.  If no improvement is achieved, hormone and further semen evaluation is indicated.  If results are normal, similar counseling is provided, and female evaluation should be considered [].  
Hormone testing may be indicated for infertile men with low sperm densities, and/or with medical evidence of endocrinopathy.  Clinically significant endocrinopathy presents as infertility is about 2% of cases []. The hormone assessment involves measurement of testosterone, follicle stimulating hormone, luteinizing hormone, and prolactin to determine if fertility is due to primary testis failure, hypogonadotropic hypogonadism, hyperprolectinemia, or androgen resistance.  Variations in these hormone level patterns can identify if any of these conditions are present [].   
Because up to 50% of male infertility may be genetic, it would seem logical to offer a genetic evaluation to most men presenting for infertility care[].  However, the only genetic testing performed routinely in clinical workup is CFTR sequencing, AZF deletion screening, and karyotyping [].  These types of testing identify a reason for male infertility in 5% of unselected patients, and about 20% of azoospermic patients [].  Indications for genetic testing include a sperm concentration of less than 10 million sperm per milliliter for men considering IVF, and azoospermia with evidence of testis atrophy.  Also, CF testing is only performed in cases of low or absent sperm in conjunction with at least one absent vas deferens, or no sperm present in the ejaculate with evidence of normal spermatogenesis.  A karyotype may be ordered if a syndrome such as Klinefelters or Kallman is suspected based on family history, body habitus, and secondary sexual characteristics [].  





Figure 1.  Algorithm for evaluation of absent or low ejaculate volume

Figure 1 illustrates the algorithm for evaluation of absent or low ejaculate volume.  Taken from Turek, P.J., Practical approaches to the diagnosis and management of male infertility. Nature Clinical Practice Urology, 2005. 2(5): p. 226-238.  Previously adapted from Nudell DM and Turek PJ (2001) Male Fertility and Infertility. In: Clinical Manual of Urology, 3rd edition, New York, McGraw – Hill Co.  

 *Reused with permission granted by the Nature Publishing Group.


Figure 2. Algorithm for evaluation of semen-abnormalities

Figure 2 illustrates the algorithm for evaluation of semen – abnormalities.  From Turek, P.J., Practical approaches to the diagnosis and management of male infertility. Nature Clinical Practice Urology, 2005. 2(5): p. 226-238.  Previously adapted from Nudell DM and Turek PJ (2001) Male Fertility and Infertility. In: Clinical Manual of Urology, 3rd edition, New York, McGraw – Hill Co.  Reused with permission granted by the Nature Publishing Group.  

*Reused with permission granted by the Nature Publishing Group.


1.3	public health relevance and disparities
Male factor infertility is of public health concern for several reasons.  Defined as the failure to conceive after twelve months of unprotected intercourse, it affects over 6 million couples in the United States, or about 10-15 percent [1].  Worldwide, the Demographic and Health Surveys program estimates that over 167 million ever – married women aged 15-49 years in developing countries (excluding China) were infertile in 2002.  In sub-Saharan Africa the infertility rates are as high as 30% [17]. 
	Nearly half of the six million infertile couples in the United States have a component of male factor infertility, and about 30% are solely caused by a male factor [18].  Male infertility can be damaging psychologically, economically, and can significantly decrease quality of life.  It is also often associated with serious medical disorders.  Reproduction is a crucial aspect of the human condition, and infertility presents a major barrier to personal fulfillment [19].  In fact, individuals with health conditions preventing them from reproducing qualify for protection under the Americans with Disabilities act following a US Supreme Court ruling classifying reproduction as a major life activity [4].  The psychological effects have even been compared to those of cancer and heart disease, and for many individuals infertility results in social isolation, clinical depression, and reduced job performance and life satisfaction.  The impacts of infertility therefore go beyond the individual, and into the social realm [20, 21].  Specifically for males, damaged psychological aspects include attitudes toward idealized masculinity, mental health, relationship satisfaction, and self-esteem [22].
	There are numerous causes of male infertility, some of which are associated with life threatening conditions, while many others have yet to be identified.  One to two percent of male infertility is caused by hypothalamic pituitary disease (secondary to hypogonadism), thirty-forty percent is caused by testicular disease, another ten-twenty percent is due to post-testicular defects (disorders of sperm transport), and as much as forty-fifty percent of male infertility is considered idiopathic [2].  Among infertile men, 20% have azoospermia or oligozoospermia (AZ/OG).  As mentioned previously, even after attempt at clinical diagnosis, about 80% of men with AZ/OG are considered idiopathic.  Nearly a third of this has been estimated to result from mutations and chromosomal abnormalities affecting germ cell production and function [23].  Thus genetic male infertility affects roughly 1 in 40 men and can be considered a common disease [3].
	From a public health standpoint, disparities related to infertility have been noted that may help identify potential avenues for intervention.  First, because social and racial disparities exist for risk factors of infertility, such as sexually transmitted infections, it is possible that preventable causes of infertility may disproportionately affect the lower classes [24].  Furthermore, male alcoholics, smokers, and those who use both have statistically significant abnormal semen analysis results, meaning they are more susceptible to the cumulative effect of causes of infertility, like effects of aging [25].  There is also evidence to suggest disparities in infertility treatment.  The costs of infertility care are often the responsibility of the patient (Table 1 shows the current mandates for insurance coverage of infertility treatment), creating significant economic and racial disparities [26]. Access to IVF is one area of concern.  One study’s findings indicated that many candidates for IVF do not pursue treatment due to financial constraints and limited access to care in states lacking mandated insurance coverage.  This study also concluded that African American couples tend to wait longer than Caucasian couples to seek fertility treatment in states with mandated insurance coverage [6].  There are also significant disparities in assisted reproductive therapy (ART) outcomes among ethnic groups.  If white women are the reference group, the odds of pregnancy were: Asian (0.86), black (0.62), and Hispanic (0.87).  In contrast, the odds of preterm birth were: Black (1.76) and Hispanic (1.22) [27].  Based on its public health significance, as well as the cost, consequences, and disparities among groups, male infertility represents an area worthy of public health intervention.  Addressing these disparities, and even simply raising awareness and educating men on avoiding environmental exposures represents an important public health initiative.     

2.0 	Public Health Intervention
2.1	Array comparrative Genomic Hybridizaiton
The striking number of men diagnosed with unexplained infertility, the rise of technology allowing infertile men to reproduce, and the potential for cost savings in the diagnostic odyssey for infertile couples together highlight the benefit of implementing a diagnostic comparative genomic hybridization chip specific for male infertility.  
	Because advanced technologies now allow previously infertile men to reproduce, the importance of genetic testing has become more apparent [1].  The principle techniques used to achieve conception for infertile men now include intracytoplasmic sperm injections (ICSI) coupled with testicular sperm extraction (TESE).  These procedures are associated with an increase in birth defect rates including hypospadias, cleft lip and palate, septal heart defects, esophageal atresia, and imprinting disorders such as Beckwith-Weidman, etc.  In 2009, Reefhuis et al analyzed data from the National Birth Defects Prevention Study, a population – based, multicenter, case – control study of birth defects, observed the following age – adjusted odds ratios for infants of ART: hypospadias [OR 2.1, 95% CI 0.9-5.2],  esophageal atresia [OR 4.5, 95% CI 1.9-10.5], cleft lip [2.4 OR, 95% CI 1.2-5.1], septal heart defects [OR 2.1, 95% CI 1.1-4.0], ventricular septal defect plus ASD [OR 2.8, 95% CI 1.2-5.1], and atrial septal defects [OR 3.0, 95% CI 1.5-6.1][28].  A six fold increase in Beckwith-Weidman is estimated in children born of ART, compared with the general population [29].  Assisted reproductive therapy (ART)-born infants now account for more than 1% of all births and 18% of all multiple births in the United States [30].  These rates are even higher in states that mandate insurance coverage for infertility treatment [31].  In Massachusetts, for example, infants conceived with ART comprise 40.5% of all multiple-birth infants [32].   Understanding the genetic pathology underlying male infertility is imperative for appropriate genetic counseling, and understanding the etiology of higher rates of birth defects among infertile couples [1].  The availability of aCGH for men undergoing ART may facilitate studies regarding the likelihood of birth defects or other genetic syndromes in their children, as well as the chances of having a child that may also be infertile.  
	Although more investigation will be required to fully understand and achieve the potential of an aCGH test specific to male infertility, there is significant evidence from the literature to support the rationale for using aCGH as a diagnostic genetic test.  Copy number variants (CNVs) are a significant source of genetic diversity with extensive differences among individuals, and also have been implicated as causative factors in complex diseases including mental retardation, schizophrenia, and cancer[33] [34].  Researchers have hypothesized that duplications and deletions, and various patterns of CNVs may cause defective recombination, meiotic failure, and AZ/OG by affecting the function of genes involved in spermatogenesis [3].  In 2011 Tuttelmann et al. performed high resolution aCGH in groups of well-characterized idiopathic infertile men with oligo and azoospermia.  The three aims of this study were (1) to determine whether the number and/or pattern of CNVs in selected men with spermatogenic failure differs from that in men with normal spermatogenesis; (2), to determine whether recurrent CNVs can be identified which might harbor genes involved in spermatogenesis, and (3) to investigate associations with reproductive parameters.  Several findings from this study indicated clinical utility for aCGH in male infertility, and that further studies are warranted in this area.  First, Tuttelmann and colleagues reported that several genes and genomic regions on autosomes and especially on the sex-chromosomes might either be risk factors or causative factors for spermatogenic failure.  Structural chromosome aberrations were also observed at higher rates in men with AZ/OG with an emphasis on autosomal translocations in oligozoospermia (3-4% vs. 0.5-1.5% in controls).  They also identified several genes that may be associated with male infertility in affected patients. They speculate that CNVs may result in altered gene transcription/protein function by mechanisms including dosage-sensitive genes in which a deletion may de-mask a recessive mutation on the homologous chromosome; genes overlapping chromosomal breakpoints may be disrupted; or CNVs might result in position effects [35].  Therefore, the authors conclude, in this first CNV study of male infertility, that there is evidence to suggest that CNVs contribute to the intricacies of male infertility.  Using this technology they also present a number of CNVs that may be risk factors for, or causative of, spermatogenic failure [3].    
	Another study, performed by Kraus et al. 2012 reported similar results using a high resolution X chromosome-specific array-CGH to detect novel CNVs in infertile men [36].  At the time of the investigation, little was known about how X-linked genes could affect male fertility.  The only well-established, recurrent genetic causes of male infertility were abnormal karyotype and Y chromosome microdeletions.  The goal of this study was to establish a more complete understanding of how X-linked CNVs and gene mutations affect male fertility.  Using this approach, Kraus and colleagues identified several patient-specific CNVs and candidate genes for spermatogenesis that warrant further exploration [36].  
	
As a potential avenue for diagnosing male infertility, identifying novel causes of male infertility, offering predictive value for infertile couples, and even cost/benefits in the diagnosis of infertility, the use of aCGH for the male infertility field in the clinical and research setting is warranted.  However, to maximize the potential efficacy of this tool several initiatives must be taken.  First, research effort is needed to discover pathogenic mutations or variants that may be identified using aCGH.  This goal may be achieved by further analyzing men with unexplained oligozoospermia and azoospermia using aCGH to find associations.  These association would then need to be characterized as pathogenic or nonpathogenic via biological functional studies which would include the utilization of mouse models or other model organisms.  
	In addition, quantifying the cost savings that could result from use of aCGH as a diagnostic tool is needed.  This goal may be achieved by predicting and/or directly analyzing the cost of outcomes averted.  In the case of male infertility, outcomes averted may include unnecessary additional testing, hospital and clinical visits, time spent at visits, anxiety and decreased quality of life caused by uncertainty of diagnosis, and even testing and treatment costs for future generations conceived via assisted reproductive technologies.  If the son of a man with a mutation known to cause infertility presents wishes to know his potential to reproduce, or if he presents to a reproductive clinic for infertility himself, the entire diagnostic workup could be avoided via a simple blood test. 
	A cursory review of the prices men might pay for infertility workup shows great potential for a microarray to cut the cost of this process; at the very least that it may be an economical option for testing men with infertility.  Common laboratory tests for diagnosing male infertility, as mentioned previously, include karyotyping, y-chromosome microdeletion testing, endocrine panels, semen analysis, infectious disease screening, and gonadotoxin exposure.  The cost of these laboratory tests are approximately $600 for a karyotype, $1,000 for y-chromosome deletion testing, nearly $100 for each hormone tested on the panel [a typical four hormone panel (testosterone, follicle stimulating hormone, luteinizing hormone, and prolactin) would cost $400], $120 dollars for an infectious disease screen, and $100 dollars per gonadotoxin exposure test [37-41].  At minimum, all of these tests combined may cost $2,000.  On the other hand, microarrays are currently being performed for as low as $200 in direct to consumer testing [41].  
	Lastly, the feasibility, as well as the willingness of physicians, hospitals, laboratories, and patients would need to be evaluated.  This evaluation could be assessed using surveys of professionals and patients.  Educating patients and professional would also help promote the practicality and utility of the program.  
2.2	Developing Array CGH for Male infertility
This section of the essay focuses on the work that I have participated in at the Magee-Womens Research Institute and Foundation (MWRI) toward developing an array specific for male infertility.  One of the primary efforts of the Yatsenko Lab at MWRI is to use array comparative genomic hybridization to discover novel genes associated with male infertility, with the long term goal of developing a microarray specific for male infertility that can be used as a simple diagnostic tool for men with non-obstructive infertility.  As described throughout this essay, using aCGH microarrays for this purpose would employ the use of a simple blood test to identify the direct cause of infertility.  Such a test would potentially avoid several other diagnostic pathways that result in great expenses and frustrations for infertile couples.  This project involves recruiting appropriate research subjects, performing aCGH on their blood samples, identifying potential causative genes for infertility, and eventually developing mouse models that can be used to validate and study these candidate genes.  This lab is also considering using lentivirus gene therapy to attempt to restore gene function in infertile male mice.  Such therapies may be offered as treatment to future generations of men with azoospermia or other sperm defects resulting in the inability to conceive children naturally.  My role in these research efforts has been in recruitment, performing essential laboratory bench work, identifying candidate genes for a gene therapy pilot project, and managing the mouse colony for this gene therapy pilot project.  
Recruitment is done primarily through the reproductive endocrinology and infertility (REI) clinic, and urology clinic at Magee-Womens Hospital of UPMC, but I have also made efforts to expand the recruitment base for the male infertility research study.  For our main recruitment I arranged to meet with nurses and doctors from both the REI and Urology clinic to determine what methods of recruitment would work best for them.  In the REI clinic, we determined that one of the nurse practitioners would compile a list of new patients visiting the clinic the week prior to their visit, so that I could plan to be in the office at that time.  This was helpful because it allowed for efficient use of my time as a part time worker, and because the most likely time for a male to come to the clinic was on the couple’s first visit.  The doctors and nurses had previously noted that men often will not return for follow up visits, especially if their semen analysis is normal.  We wanted to contact the men on their first visit because we were interested in recruiting them whether they were infertile or not; both a control population and an affected (infertile) population were required for our study.  At the time of the couple’s visit the medical assistant would inform me if a male was present, and also ask the couple if they would be willing to be seen by someone recruiting patients for a study.  If the couple granted permission, I would enter the room between the time the patients were placed in the private room by the medical assistant and the time they were seen by the physician.  Describing the study to the patients, determining if they were interested in participating, and consenting the patients for the study typically took between 10 and 15 minutes.  The men who agreed to take part in the study were then asked to have their blood drawn at the hospital’s lab services, for which I provided them a script.  Recruitment was performed similarly at the Urology clinic, but because all of the patients in the clinic were men, I was not concerned whether they were new or returning patients.  Thus, I attempted to recruit all the patients who came through the clinic whenever I was able to be present in the office.  I also posted flyers throughout the clinics, developed contact information forms, and information forms about the study for the medical assistants and nurses to distribute to the patients.  Prior to the distribution of these three documents for the study, I obtained approval from the Institutional Review Board at the University of Pittsburgh.
To expand the recruitment base of the study, I advertised our research via online media, social networks, and other infertility clinics in the greater Pittsburgh area.  These efforts of expansion also required the institutional review board’s approval prior to use.  First, I wrote a section describing the study, and how to contact the study investigator if individuals were interested in participating.  This section, (that I subsequently posted on online mediums) required IRB approval to determine whether it was appropriately advertising the study, free of coercion, and that it would not be biased toward a specific ethnic or socioeconomic group.  I posted the advertisement on the following media, including: Facebook groups for infertility and male infertility.  I also posted the advertisement onto other forums meant for couples struggling through infertility, as well as forums that were specific to male infertility.  Lastly, the advertisement was posted and distributed by infertility support groups, hotlines, and other reproductive and infertility clinics in the Pittsburgh area.  Through this expansion, I was able to recruit several individuals outside of the clinics within Magee-Womens Hospital, and I received interest in the study from men throughout the United States.   
Another project I am involved in is an experimental lentiviral gene therapy aiming to restore fertility in infertile, but otherwise healthy and viable male mice.  A project that is now in the breeding phase, I began by identifying several candidate genes that the therapy could potentially target.  The goal was to find a single gene target knocked out in male mice.  The criteria for this target gene were:  proven to cause infertility, especially non-obstructive azoospermia or oligozoospermia, in otherwise healthy male mouse knockouts; the primary defect in the gene must be due to its expression in sertoli cells, not germ cells; and the cause of infertility must be realistically amenable to gene therapy.  We wanted to target sertoli cells rather than germ cells to avoid the ethical implications of potentially altering the genetic makeup of future generation through this therapy.  Also, to expand on the third criterion, we were hoping to find a gene in which the mouse knockouts affected a limited number of steps in spermatogenesis, rather than an earlier developmental process that would render any response to gene therapy impossible.  For example, if the gene were known to cause genital abnormalities, which begin to develop in the embryonic state, a gene therapy intervention at day 15 or beyond of the mouse’s life would have no effect on fertility.  A fourth criterion that was relaxed in the later stages of searching for a candidate gene was that the gene must only be expressed in the mouse testes.  This criteria was initially set in order to avoid potential side effects caused by the gene therapy.  This condition, however, was disregarded due to the difficulty of finding a gene that fit all four of the criteria.  Furthermore, because the vector was going to be injected directly into the testes, we thought there would be low potential for it to affect other organs or systems.  Lastly, due to time and personnel constraints, the gene in question would need to have an available mouse line being maintained by another investigator or available through a commercial mouse repository.  After considerable investigation, we determined that the therapy would be attempted on male mice with the DNAJA1 gene knocked out.  There was strong support in previous publications that DNAJA1 homozygous male knockouts were viable but infertile, with a primary defect in steps 8 and 9 of spermatogenesis caused by lack of expression in the sertoli cells.  Fortunately, the Jackson Laboratories also maintained live heterozygous knockouts for this specific gene.  
We are now breeding a mouse colony of our own with this gene knocked out, and are awaiting the birth of a homozygous knockout pup for the experimental therapy.  Once this pup reaches the age of 14 days, the therapy will be injected into the testes, and we will pair it for mating to determine whether it will reproduce.  At this point, we will perform histological studies on the testes, and semen analysis, to study the expression of the gene therapy, and to characterize the sertoli cells and sperm production.  
If this gene therapy is successful, the principle investigator may perform additional gene therapy experiments in mice with candidate genes for male infertility that were identified via aCGH analysis knocked.  Because the likelihood of finding mouse lines available for these gene knockouts from other investigators or mouse repositories is low, these genes will be knocked out using clustered regularly interspaced short palindromic repeats, or CRISPRs.  The CRISPR system enables the creation of mouse models and reduces the time required to weeks, rather than months or even longer.  

3.0 	Conclusions
Male infertility of genetic origin affects nearly 1 in 40 adult men and thus, may be considered a common disease. Male infertility has significant psychological and economic burdens on individuals, couples, and society.  As with any other public health concern, efforts should be made to minimize the burdens to all stakeholders, especially those individuals that are directly affected by the disease.  One appropriate target to reduce the economic burden of the disease, and its disparate effects on subgroups of the population, is to reduce the cost of diagnosing and treating male infertility.  This outcome would also improve diagnostics for the many men whose infertility remains unexplained.  Currently, most patients are often directly responsible for these costs, as demonstrated in Table 1.  Also, genetic testing is not typically part of the diagnostic procedure, and is rarely paid for by insurance.  This situation remains even as the knowledge of genetic etiologies grows, and previously infertile men are able to conceive children through assisted reproductive techniques, rendering the knowledge of inheritable conditions of increasing importance.  The ideal tool for this effort would be an inexpensive genetic test whose clinical utility encompasses the majority of genetic etiologies.  
Although more work is needed to realize its full potential, some evidence suggests that array comparative genomic hybridization (aCGH) at the genomic level may be an economical option to improve the diagnosis of male infertility[3, 33, 36].  Compared to the typical diagnostic workup for infertility (including biochemical, cytogenetic, and molecular testing) aCGH is relatively inexpensive.  It is also capable of detecting the majority of genetic etiologies for which genetic testing is currently done, at reduced cost.  There remains much to be learned about genetic causes of male infertility, a challenge that is being investigated by the Yatsenko Lab of Magee-Womens Research Institute and Foundation via familial and individual based genome wide aCGH, whole exome, RNA expression, and mouse studies.  This research is being done with the goal of reducing the burden of infertility for all involved, and with the hope that a comprehensive genetic test, done via a small blood draw from the patient, will be used as a first – line diagnostic measure for male infertility.  
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